Over the last 30 years, Andro and three of its derivatives DASS (14-dehydroxyandrographolide-12-sulfonic acid sodium salt), DDAS (14-dehydroxy-11,12-didehydroandrographolide-3,19-bis (sulfonic acid) potasium sodium salt), and DDAP (14-dehydroxy-11,12-didehydroandrographolide-3,19-bis (sulfonic acid) potasium salt) ( Fig. 1 ) have been used clinically in China. These drugs are effective in relieving the symptoms of inflammation, fever, and pain due to bacterial and viral infections. [22] [23] [24] [25] [26] DASM (14-dehydroandrographolide succinic acid monoester), a derivative of Andro, was found to be an inhibitor of human immunodeficiency virus (HIV) in vitro. 27) Andro was found to decrease the HIV-1 RNA level and increase CD4 ϩ lymphocyte count in HIV-positive patients. 28) Additionally, recent research found that Andro has a broad range of anticancer activity. [29] [30] [31] [32] To expand or enhance the bioactivity, many new Andro derivatives have been synthesized over the last 20 years. Recently, we have synthesized several Andro analogues and investigated their antibacterial activity and mechanism of action. Some of these compounds had significant activity against Staphylococcus aureus. 33) Among the new compounds is a conjugate of Andro and lipoic acid, 14-a-lipoyl andrographolide (AL-1) (Fig. 1) . AL-1 significantly reduces virulence factor production and inhibits bacterial growth and the quorum sensing system. 33) Although the Andro class of drugs is widely used to treat respiratory infections, their activity against the influenza virus has rarely been reported. In this report, the activity of Andro, DASS, and AL-1 on influenza and avian influenza viruses both in vivo and in vitro were evaluated, and their mechanism of action was investigated.
Activity of Andrographolide and Its Derivatives against Influenza Virus in Vivo and in Vitro

MATERIALS AND METHODS
Compounds Andro and DASS were purchased from Chengdu Natural Medicines Research Center (Sichuan, China). AL-1 was synthesized in our laboratory. Ribavirin was purchased from Star Lake Bioscience Co., Inc. (Zhaoqing, China). Oseltamivir phosphate was purchased from the Shanghai Branch of Roche Pharmaceuticals Inc. (Shanghai, China). For mouse experiments, AL-1 was dissolved in dimethyl sulfoxide (DMSO) and emulsified with Tween-80 and then diluted with sterile saline, and Andro was dispersed with 0.3% carboxymethylcellulose. The other drugs were dissolved in sterile saline. For cell experiments, Andro and AL-1 were dissolved in DMSO and then diluted with phosphate buffered salin (PBS) (free of Ca, Mg). The final concentration of DMSO in each culture medium was not more than 0.5%. The other drugs were dissolved in PBS (free of Ca, Mg).
Viruses and Cells Avian influenza A/Chicken/Guangdong/96 (H9N2) virus and A/Duck/Guangdong/99 (H5N1) virus were obtained from the Veterinary Technology Center of South China Agricultural University (Guangzhou, China). Influenza A/PR/8/34 (H1N1) virus was provided by the Chinese Center for Disease Control and Prevention (Beijing, China). Madin Darby canine kidney (MDCK) cells were obtained from the Center of Experimental Animals of Sun Yatsen University (Guangzhou, China). The viruses used in cell culture experiments were passaged in MDCK cells at least once to prepare pools. Three virus strains were propagated in specific pathogen-free embryonated eggs. The A/Chicken/ Guangdong/96 (H9N2) virus was adapted for lethality in mice after nine passages in the animals. The A/Duck/Guangdong/99 (H5N1) virus and A/PR/8/34 (H1N1) virus were adapted for lethality in mice after five and three passages in the animals, respectively. Three virus strains recovered from the lungs were propagated again for in vivo antiviral studies.
Animals Female specific pathogen-free BALB/c mice (13-15 g) were obtained from the Guangdong Medicinal Laboratory Animal Center (Nanhai, Guangdong, China). They were quarantined for 24 h prior to use and fed standard mouse chow and tap water. The mice were infected via intranasal instillation after anaesthetized with ether vapor and 4 drops per mouse with a 1-ml syringe (total 0.05 ml). All experiments involving in H5N1 virus were carried out in an animal P3 level laboratory.
Determination of LD 50 of Influenza Viruses in Mice Groups of 10 mice (13-15 g) were infected by intranasal instillation of five concentrations of virus in serial 10-fold dilutions in LB broth. Animals were observed daily for 21 d. The LD 50 value was calculated according to the Reed-Muench method.
34)
Lung Virus Titer Determination The mouse lungs were homogenized in minimum essential medium (MEM). Each lung homogenate was centrifuged at 3200ϫg for 5 min, and varying dilutions of each supernatant were assayed in triplicate for infectious virus in MDCK cells grown in 96-well flat-bottomed microplates. Lung virus titers were determined using the NR uptake assay as described by Sidwell et al. 35) and Smee et al.
36)
In vivo Toxicity Determination Andro, DASS, and AL-1 were each evaluated for the dose considered lethally toxic to mice by treating 10 mice per dose group with each compound. Based on previous toxicity results, the AL-1 doses used were 1600, 1200, 800, 400, and 200 mg/kg/d. Andro and DASS doses were 4000, 3000, 2000, 1000, and 500 mg/kg/d. Drugs were administered by oral gavage twice daily for 7 d. The animals were weighed prior to the first treatment and again 24 h after the final treatment. Deaths were recorded daily for 21 d.
Evaluation of Antiviral Effects in a Prophylaxis Model The animals were anesthetized by inhalation of ether vapor and then an approximate 2ϫLD 50 amount of virus (50 ml) was instilled onto the nares. Viruses studied in vivo included H9N2, H5N1, and H1N1. The mice were treated with drugs orally twice daily for 7 d beginning 24 h before viral exposure. Groups of 6 mice were killed on day 4 to determine the lung parameters.
Evaluation of Antiviral Effects in a Therapeutic Model To determine the therapeutic efficacy against the influenza A virus, mice (10/group) infected with H9N2 virus were treated orally twice daily for 7 d with the test agent beginning 24 h before viral exposure and 4, 24, 48, and 72 h after viral exposure. Ribavirin and oseltamivir phosphate were used as positive controls. The prevention of death by day 21 and increase in mean days to death (MDD) were recorded.
Antiviral Evaluation in Vitro The plaque reduction assay was used to determine in vitro antiviral activity. Confluent monolayers of MDCK cells, cultured in a 6-well tissue culture plate, were infected with approximately 300 PFU/ml of the H9N2 virus. After 1-h incubation at 37°C, the viruscontaining supernatant was removed by aspiration, and the cells were washed twice with prewarmed MEM and replaced with overlay medium (Dulbecco's modified Eagle's medium (DMEM) containing penicillin 100 U/ml, strepto-mycin 100 mg/ml, trypsin 10 mg/ml and 1% low-melting agarose) containing the test agents at different concentrations. The cultures were incubated for 2 to 3 d at 37°C in 5% CO 2 , and the cell monolayer was fixed with a 4% formaldehyde solution for 30 min. The agarose was removed with flowing water, and plaques were stained with 0.75% crystal violet diluted in 100% methanol. The plaques were counted by visual examination, and the degree of plaque inhibition was calculated relative to the control. Antiviral activity was expressed as the 50% effective (virus-inhibitory) concentration (EC 50 ) determined by plotting the compound concentration versus percentage of inhibition on semilogarithmic graph paper. 37) Determination of Cytotoxicity The 3-(4,5-dimethylthiazol-2-yl)-3,5-diphenyltetrazolium bromide (MTT) assay was used to determine the cytotoxicity of Andro and its derivatives. MDCK cells were grown (less than half confluency) in 96-well plates for 24 h. The media was replaced with medium containing 2-fold serial diluted drugs, and the cells were further incubated for 48 h. The culture medium was removed and 20 ml of MTT (Sigma) solution (5 mg/ml in PBS) was added to each well and incubated at 37°C for 4 h. After removal of the supernatant, DMSO 100 ml was added to solubilize the formazan crystals, and the culture was incubated for 30 min. The optical density was measured at 540 nm in an ELX800-UV ELISA reader.
37) The 50% cytotoxity concentration (CC 50 ) value was calculated as the concentration that decreased the number of viable cells to 50% of the untreated controls. The selectivity index (SI) was calculated as CC 50 /EC 50 .
Hemagglutination Inhibition Assay The hemagglutination inhibition (HI) assay was employed to investigate the effects of Andro and its derivates on viral adsorption onto target cells. Chicken erythrocytes supplemented with 1.6% sodium citrate in sterile water were separated by centrifugation (800ϫg, 10 min, room temperature) and washed three times with sterile PBS. Drug solutions (50 ml) in serial 2-fold dilutions in PBS were mixed with an equal volume of influenza virus solution in 1/512 dilutions from virus stocks (HI titers: 2 11 ). After incubation for 45 min at room temperature, 100 ml of the solution was mixed with an equal volume of 1% chicken erythrocyte suspension. The solution was incubated for 30 min at room temperature. In the samples in which viruses were preincubated with compounds, up to a certain dilution the viral particles were no longer capable of agglutinating erythrocytes, indicating an interaction of the compound with the viral hemagglutinin.
Statistical Analysis Data are expressed as meanϮS. Increases in the number of survivors were evaluated using c 2 analyses with Yates' correction. Differences in MDD, lung parameters, lung virus titers, and EC 50 and CC 50 in MDCK cells were analyzed using Student's t-test.
RESULTS
Comparison of Murine Toxicity
Oral gavage administration to mice using a twice-daily schedule for 7 d showed that Andro and DASS had very low toxicity with LD 50 values of Ͼ4000 mg/kg/d; whereas AL-1 was more potent with an LD 50 value of approximately 1243 mg/kg/d ( Table 1) . Death of mice was observed when AL-1 800 mg/kg/d was administered.
Comparison of in Vivo Anti-influenza Virus Efficacy In the prophylaxis model, Andro, DASS and AL-1 were evaluated against influenza H9N2, H5N1 and H1N1 in mice ( Table 2 ). The day 4 lung index and lung virus titers were determined, because at this time lung consolidation and weights are maximal; day 8 mean body weight changes were recorded because the mice were treated with the test compounds for 7 d. In mice infected with all viruses tested, ribavirin at a dose of 150 mg/kg/d completely prevented death and significantly improved other parameters. AL-1 demonstrated considerable inhibitory effects against the tested viruses. Against H1N1 infection, AL-1 completely prevented deaths at 200 mg/kg/d; After infection with the A/H9N2 and A/H5N1 strains, 80% of mice survived in both the AL-1 200 mg/kg/d and 100 mg/kg/d groups. The other parameters were also significantly inhibited at both doses. It should be noted, however, that in the A/H1N1 experiment, 25% of placebo-treated controls survived, whereas in the A/H9N2 and A/H5N1 experiments, the viral challenge appeared to be higher since none or only 10% of placebo-treated controls b) The animal number used to assay survival, MDD and mean host weight change. c) Mean day to death of mice dying prior to day 21. d) The animal number used to assay lung index and lung virus titer were 6 for drugs and 10 for saline groups, respectively. e) Lung indexϭ(lung weight/body weight)ϫ100%. f ) Lung index inhibition rateϭ(mean lung index of saline groupϪmean lung index of drug group)/Mean lung index of saline group ϫ100%. * pϽ0.05; ** pϽ0.01; *** pϽ0.001.
survived. Andro and DASS provided lower protection to mice infected with influenza viruses compared with ribavirin and AL-1. For Andro and DASS, 500 mg/kg/d was the most effective dose with a 50% and 40% survival rate, respectively, after infection with the A/H9N2 and A/H5N1 viruses. A 90% and 60% survival rate was achieved after infection with the A/H1N1 virus at the same dose. At the highest dose (Andro and DASS 2000 mg/kg/d and AL-1 400 mg/kg/d), no obvious toxicity was observed in healthy mice in the toxicity assay. The most effective dose was 500 mg/kg/d for Andro and DASS and 200 or 100 mg/kg/d for AL-1 depending on the virus strain.
Effects of Delayed Therapy The results of delaying initiation of therapy with AL-1 in influenza A/H9N2 viral infection are presented in Table 3 . In this experiment, AL-1 200 mg/kg/d, the optimal dose in a prophylaxis setting, was used. Oseltamivir 100 mg/kg/d and ribavirin 150 mg/kg/d were used as positive controls. Overall, oseltamivir gave higher protection to the mice than ribavirin and AL-1 with all delayed-therapy protocols. AL-1 was less effective than ribavirin in protecting against lethality and MDD. For all the compounds, the best protection occurred when administered 4 h after viral exposure. Oseltamivir, ribavirin, and AL-1 given 24 h after viral exposure resulted in 8/10, 5/10, and 4/10 survival rates, respectively. When therapy was initiated 72 h after viral exposure, no compound showed protection against lethality compared with the saline-treated controls.
Evaluation of Anti-Influenza Viral Activity in Vitro The antiviral activity of Andro, DASS, AL-1, and ribavirin were evaluated by plaque reduction assay using MDCK cells. The results are summarized in Table 4 . Among the four compounds, AL-1 exhibited the most effective antiviral activities with EC 50 values ranging from 7.2 to 15.2 mM, depending upon the virus assayed. Andro and DASS were less potent with EC 50 values ranging from 94.3 to 121.7 mM for Andro and from 142.2 to 222.9 mM for DASS. Ribavirin exhibited slightly lower antiviral activity compared with AL-1 with EC 50 values ranging from 30.3 to 42.9 mM. However, AL-1 was the most toxic to MDCK cells with a CC 50 value of 785 mM. Andro, DASS, and ribavirin were less toxic with CC 50 values of 3085, 3720, and 2450 mM, respectively. The SI of AL-1 was approximately 2-5 fold greater than that of Andro and DASS, and equal to or slightly greater than that of ribavirin, depending on the virus assayed. These results demonstrate that AL-1 has a much higher therapeutic index than both Andro and DASS and is better than or at least equal to ribavirin in the experiments performed.
Inhibition of AL-1 on Viral Binding to Chicken Red Blood Cells Influenza A viruses have the ability to bind to chicken red blood cells (RBCs), resulting in hemagglutination. To investigate whether Andro compounds prevent virus particle binding to cell surface receptors, we employed HI assays, and the results are summarized in Table 5 . AL-1 exhib- a) The values represent the meanϮS.E.M. of three independent experiments; MIC represents the minimum concentration of compounds necessary to completely inhibit binding of virus to chicken red blood cells by hemagglutination inhibition assay.
ited the most effective inhibition of viral binding to RBCs in the concentration range of 5.3-16.8 mM, depending on the virus assayed. Andro and DASS did not show any inhibition at a concentration Ͼ180 mM. Ribavirin did not show any inhibitory effects in this assay. This was expected because ribavirin acts by interfering with the replication of viral RNA. It can be concluded from these results that AL-1 is capable of directly interfering with viral HA binding to RBC surface receptors, exerting a therapeutic effect.
DISCUSSION
Influenza A viral infection is still a major health burden, and the options for the control and treatment of the disease are limited. Highly pathogenic H5N1 influenza A viruses have spread relentlessly across the globe since 2003, more than 300 infections in humans have been reported, and the mortality rate is 60%. The threat of a new pandemic requires the development of new therapeutic agents. In this report, we showed that the recently synthesized AL-1 is highly active against influenza A viruses, including the H5N1 strain. AL-1 is active in both prophylaxis and treatment in mouse infection models. In the prophylaxis model, efficacy was demonstrated in all disease parameters studied in these experiments, including prevention of death, increase in the MDD, reduction in body weight decline, inhibition of lung consolidation, and reduction in titers of virus recovered from the lungs. The optimal dose of AL-1 against H9N2 and H1N1 was 200 mg/ kg/d with 80% and 100% survival rates, respectively. For H5N1, the optimal dose was 100 mg/kg/d with an 80% survival rate. In the therapeutic model, AL-1 was less efficacious than oseltamivir and slightly less efficacious than ribavirin against lethality when treatment began 24 h after viral exposure.
In this study, Andro and its derivative, DASS, which have been widely used to treat respiratory infections in China, were less effective than AL-1 in both the in vitro and in vivo assays. These data were in agreement with a previous report that AL-1 was much more active than Andro and other Andro derivatives against bacteria. 33) Several investigations on the mechanism of action of Andro have been reported. Activation of the transcription factor nerve factor-kappaB (NF-kB) is critical for tumor necrosis factor-a-induced inflammatory response. Xia et al. 38) and Hidalgo et al. 39) reported that Andro potently inhibits NF-kB activation in vivo in a dose-dependent manner by binding to the reduced cysteine 62 of p50, thereby inhibiting the binding of NF-kB to DNA. Andro and its derivatives inhibit HIV by two mechanisms distinctly different from those of other drugs. It inhibits proprotein convertases, which cleave the HIV envelope glycoprotein gp160, thereby preventing the binding of the virus to T cells. It also suppresses viral replication by inhibiting virus-infected cell proliferation. 40 ,41) Although we did not investigate the mechanism of action of AL-1 in this study, we hypothesize that AL-1 may act by: i) inhibiting NF-kB activation, thereby alleviating inflammation; and ii) blocking viral binding to RBCs.
Although AL-1 was less potent than oseltamivir and slightly less potent than ribavirin in the influenza prophylaxis and therapeutic models, it may have several advantages as an antiviral agent. First, AL-1 exerts its antiviral activity by mechanisms of action different from that of oseltamivir and ribavirin. Thus AL-1 maybe used in combination therapy with other antiviral drugs. Second, due to the nature of its multiple mechanisms of action, AL-1 may not easily induce drug resistance.
The present study demonstrated that AL-1 is a more potent agent against human influenza virus than Andro and DASS, which have been used clinically for decades. The efficacy against the influenza H5N1 subtype both in vivo and in vitro suggests that it may be of use against the current epidemic of highly pathogenic avian influenza occurring in human populations. Detailed studies of the mechanism of action, synergistic effects with other antiviral agents, administration route and schedule, and clinical relevance for controlling the currently circulating human influenza and emerging avian influenza viruses remain to be explored.
